Genentech, Inc., founded in 1976 and headquartered in South San Francisco, California, is a pioneering biotechnology company dedicated to developing innovative medicines to treat serious medical conditions. The company is renowned for its focus on biologics and has a strong portfolio of targeted therapies for cancer and other diseases, including its flagship products such as Avastin and Herceptin.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| ROSW 5.25% 2035-07-15 USDGenentech, Inc. | United States | 2035-07-15 | 5.250 | 5.36 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Genentech has a history of issuing bonds since the early 1990s to support its expansion and research initiatives. Notably, in 2019, the company issued a $2 billion bond to finance its ongoing projects, which has contributed to its impressive growth in the biotech space. As of 2023, Genentech's bonds yield comparably to the industry average, reflecting investor confidence despite significant capital requirements typical in biotech ventures. The company’s bonds are often characterized by their callable features, providing potential flexible repayment options.